Method of preparing benzodiazepinone derivatives or their salts

专利摘要:
Compounds of the formula <IMAGE> (I) wherein A is alkylene of 1 to 5 carbon atoms; R1 is amino, tert.butylamino, N-cyclohexyl-N-methyl-amino, dibenzylamino, benzylamino, trimethoxybenzyl-amino, 1-ethyl-2-pyrrolidinylmethylamino, 1-ethyl-3-piperidinyl-amino, 9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl, 1,2,5,6-tetra-hydro-1-pyridyl, 4-benzyl-piperidino, 1,2,3,6,7,8,9,9a-octahydro-4H-pyrazino[1,2-a]-pyrimidine-1(or-8)yl, 3- or 4-hydroxypiperidino, 3-or 4-methoxypiperidino, 1,2,3,4-tetrahydro-2-isoquinolyl, 3-azaspiro[5.5]undecan-3-yl, 4-oxo-piperidino or the ethyleneketal thereof, hexahydro-3-methyl-1-pyrimidinyl, thiomorpholino, 1-oxido-thiomorpholino, hexahydro-4-methyl-1H-1,4-diazepin-1-yl, 2,6-dimethyl-morpholino,1,4-diazabicyclo [4.3.0]nonan-4-yl, 1,2,5,6-tetrahydro-pyrid-1-yl, (1-methylpyrrolindin-2-yl)-ethylamino, (1-methylpyrrolidin-2-yl)-methylamino, (1-n-propylpyrrolidin-2-yl)-methylamino, (1-allyl-pyrrolidin-2-yl)-methylamino, (1-n-butyl-pyrrolidin-2-yl)-methylamino, (1-benzyl-pyrrolidin-2-yl)-methylamino, (furan-2-yl)-methylamino, (tetrahydrofuran-2-yl)-methylamino, N-[(1-ethyl-pyrrolidin-2-yl)-methyl]-methylamino, (1-ethyl-pyrrolidin-3-yl)-methylamino or (1-allylpyrrolidin-3-yl)-methylamino; or, when A is alkylene of 2 to 5 carbon atoms, also dimethylamino, diethylamino, dipropylamino, diisopropylamino, di-n-butylamino, diisobutylamino, pyrrolidino, piperidino, methyl-piperidino, ethyl-piperidino or morpholino; and R2 is hydrogen, methyl or ethyl; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as the salts are useful as anti-ulcerogenics and secretion inhibitors.
公开号:SU797578A3
申请号:SU782621051
申请日:1978-05-29
公开日:1981-01-15
发明作者:Шмидт Гюнтер；Лейтольд Матиас
申请人:Др. Карл Томэ Гмбх (Фирма)；
IPC主号:

专利说明:

(54) A method for producing benzodiazepinone derivatives or their salts with ethyl, or a morpholino group, if A is an unbranched alkylene group with 2-5 carbon atoms, or their salts. The purpose of the invention is to obtain new useful compounds that expand the arsenal of means of action on a living organism. The goal is achieved by synthesizing the latter based on the known amination reaction of haloalkyls with secondary amines. The reaction is usually carried out in an inert organic solvent (alcohols, toluene ether, etc.) at a temperature. from room temperature to the boiling point of the solvent; Preferably the presence of a hydrogen halide binder, in which either an excess amine secondary is used, or an alkali metal carbonate or bicarbonate 1. Benzodiazepinone derivatives of general form 1 are obtained by reacting a compound of the general formula Pcc: in "CO-A-HQl where RI and And the above values, and On. means a halogen atom; with a compound of general formula III, RI is H, where RI is as defined above. The reaction is preferably carried out in an inert solvent at a temperature from room temperature to the boiling point of the solvent. Alcohols are suitable as solvents, such as zanol, n-propanol, isopropanol, ketones, such as acetone, or ethers, such as dioxane or tetrahydrofuran, aromatic hydrocarbons, such as benzene or toluene. It is advisable to carry out the reaction in the presence of a hydrogen halide binder, which can be used as an excess of a compound of formula (HP) or an alkali metal carbonate or bicarbonate, or a tertiary organic amine. The compound of general formula (T) is isolated in free form or as a salt with an inorganic or organic acid, such as, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, tartaric, citric, fumaric, maleic, succinic or oxalic acids. Example 1. 11- {(1-Etsh1-2-pyrrolidinyl) - methylamino acetyl-5,11-dihydro-5-methyl-6H-pyrido 2, 3-Ы 1,41benzodiazepin-6-one. 9.0 g of 11-chloroacetyl-5,11-dihydro-5-methyl6H-pyrido 2, 3-Ы 1.41-benzodiazepin-6-one. 3.5 g of sodium carbonate and 4 g of 1-ethyl-2-aminomethyl-pyrrolidine in 100 ml of ethanol are refluxed for 1.5 hours. Sucked off in a hot state, the filtrate is evaporated to dryness and the residue is recrystallized from acetonitrile and then from ethyl acetate. Melting point 169-171 ° C, yield 48% of theory. Dihydrochloride: t. LOi. 196-198 ° C (from ethanol). Example 2. 5,11-Dihydro-1 and (4-methoxypiperidino) acetyl-bH-pyrido 2,3-Ü 1-4 benzo D1-azepin-6-one. 5.9 g of 11-chloroacetyl-5,11-dihydro-6H-pyrido 2,3-b 1,4 benzodiazepin-6-one and 15 ml of 4-methoxypiperidine in 200 ml of benzene are boiled under reflux for 15 hours The mixture is filtered off with suction, the solvent removed and the residue recrystallized from isopropanol. Melting point 219-220 ° C, yield 55% of theory. Example 3. 11-Dibenzylamino-acetyl-5, 11-dihydro-6H-pyrido 2,3-1,4 1,4 benzodiazepIN-6-OH. 6 g of 11-chloroacetyl-5,11-dihydro-6H-pyrido 2,3-b 1,4 benzodiazepin-6-one, 4.2 g of dibenzylamine and 2.1 g of triztilamine in 100 ml of absolute dioxane are heated under reflux in for 15 hours. After cooling, the resulting triethylamine hydrochloride is separated, the filtrate is evaporated to dryness in vacuo. The residue is recrystallized twice from ethanol. Melting point 187-189 ° C, yield 60% of theory. Example 4. 5,11-Dihydro-11- 3- (2-megylpiperidino) propionyl-bH-pyrido 2,3-1,4 1,4 benzodiazepine 6-one. To 16 g of 11- (3-chloropropion-1) -5,11-dihydrobH-pyrido 2,3-b 1,4-benzodiazepin-6-one in 200 ml of isopropanol are added 20 ml of 2-methylpiperidine, and refluxed the solution is evaporated to dryness for 1 h and vacuum. The residue is mixed with water, alkalinized with ammonia and extracted with chloroform by shaking. The residue of the chloroform extract is purified on a column of silica gel. The eluate is evaporated in vacuo and the residue is recrystallized from isopropanol. Melting point 197-199 ° C (with decomposition), yield 65% of theory. Example 5. 11- (3-Benzylamino) -propion-5, ll-dihydro-6H-pyridb 2,3-Ü 1,4 benzodiazepin-6-one. 6.0 g of 11- (3-chloropropionyl) -5,11-dihydro-bN-pyrido 2,3-b 1,4 benzodiazepin-6-one. 2.3 g of sodium carbonate and 4.4 i of isylamine in 80 ml of ethanol are heated under reflux for 4 hours. The mixture is sucked off in a hot state, the alcohol is distilled off and the residue is purified on a column of silica gel. The eluate is evaporated and the residue is twice recrystallized from n-propanol. Melting point 155-158 ° C, yield 41% of theory. Example 6. Hydrochloride (dystilamino) butyryl 1-5,11-dihydro-5-methyl-6H-pyrido (2,3-Ь 1,4 benzodiazepin-6-one. 4.3 g of 11- (4-chlorobutyryl) - 5,11-dihydro-5-methyl-bH-pyrido 2,3-b 1.41 benzodiazepin-6-one and 1.9 g of diethylamine in 70 ml of dimethylformamide are left to stand at room temperature for three weeks. Vacuum dry and the residue is recrystallized from isopropanol Hydrochloride is obtained with a melting point of 233-235 ° C. Yield 54% of theory Example 7 5.1 l-Dihydro-ll- (4-pyrrolidino-butyl) -6H-pyrido 2 , 3-Ь 1,4 benzodiazepin-6-one 5.5 g 11- (4-chlorobutyryl) -5,11-dihydro-6H-pyrido 2 , 3-Ь 1,4 6enzo: shazepin-6-oia, 1.4 g of pyrrolidine and 2, G of sodium carbonate in a mixture of 80 ml of absolute ethanol and 20 ml of absolute dioxane are heated with a reverse cooling of NIKOM for 10 hours. when hot, the filtrate is evaporated in vacuo to dryness and the residue is purified on a silica gel column. The eluate is evaporated to dryness and the residue is recrystallized from acetonitrile. Melting point 163-165 ° C, yield 55% of theory. Example 8. 11- (1-Ethyl-3-piperidyl) -aminoacetyl-5,11-dihydro-6H-pyrido 2,3-b) 11.4 benzodiazepin-6-one. 1.2 g of 11-chloroacetyl-5,11.dihydro-6H-pyrido 2,3-b 1,4 benzodiazepine, 2.8 g of sodium carbonate and 3.8 g of 1-ethyl-3-aminopiperidine in 100 ml of ethanol are heated it was cooled with a nickname for 5 hours. The mixture was sucked off in a hot state, the filtrate was evaporated to dryness and the residue was purified on a column of silica gel. The eluate is evaporated and the residue is recrystallized from ethyl acetate. .. Melting point 147-148 ° C, yield 58%. theories. Example 9. 5,11-dihydro-11-t dihydrochloride (hexahydro-4-methyl-W-1,4-diazepin-1-yl acetyl-bH-pyrido 2,3-1,4 benzodiazepin-6-o 8 6 g of 11-chloroatel-5, 1-dihydro-6H-pyrido 2,3-b 1,4 benzodiazepin-6-one, 3.5 g of sodium carbonate and 4.5 g of hexahydro-1-methyl-1H-1 The 4-diazepyrsh in 100 ml of ethanol is refluxed for 2.5 hours. The mixture is sucked off in a hot state, the alcohol is distilled off and the residue is triturated with lyoxane. The resulting crystals are dissolved in ethanol and added with concentrated hydrochloric acid converted to dihydrochloride. After recrystallization from 94 / s-but ethanol gives the above dihydrochloride with a melting point of 241-243 ° C. (. decomposition). Yield 47% of theory. Example 10. 5,11-Dihydro-1 l- (5-pyrrolidino-valeryl) -6H-pyrido 2,3 -L 1.4 benzodiazepin-6-one .4.5 g 11- (5-chlorovaleryl) -5,11-dihydro-6H-pyrido 2,3-b 1,4 benzodiazepin-6-one and 10 ml of pyrrolidine 100 ml of ethanol is refluxed for 12 hours. The alcohol is distilled off, the residue is dissolved in chloroform / water, the organic phase is evaporated to dryness and the residue is recrystallized from ethyl acetate. Melting point 156-157 ° C. Yield of 45% of theory. Example 1L 11 - {(1-Benzyl-2-pyrrolidinyl) methylamino-acetyl-5,11-dihydro-5-methyl-bH-pyrido 2,3-Ü 1,4 benzo; shazzin-6-one. 14.3 g of p-chloroacetyl-5, p-dihydro-5-megyl-bH-pyrido 2,3-b 1,4 benzodiazepin-6-one, 5.3 g of sodium carbonate and 11.4 g of 2-aminomethyl-benzyl pyrrolidine in 300 ml of absolute dioxane is boiled under reflux for 2 hours. The mixture is sucked in a hot state, the dioxane is distilled off and the residue is purified on a silica gel column. The eluate is evaporated and the residue is twice recrystallized from ethyl acetate. The melting point m 123-124 ° C, the output of 47% of theory. The purification of the crude product indicated in examples 4, 5, 7, 8 and 11 by silica gel column chromatography was carried out using a mixture of chloroform, methanol, cyclohexane and concentrated ammonia in a ratio of 68: 15: 15: 2 as a solvent and eluent. Analogously to Examples 2-11, the compounds listed in Table 2 are prepared. one.
(
GL

o
a
fS
S &
m
&
7
(N
5, K o S
I
about
I
a-o a
9 f and S
s MS CT)
a
u
four
§five
a.
§ Fr.
eight
L1 E;
- r о 01О
71
I S -e00 and Si
g 5s
I
a: u
I
CJ
K (
QC
as o
to
f
u
| 0, 0gP
5 Sg s
in j "
W W
to
SLCO
s
about
/
/
f
2; I
w "
SCh4
Oh oh
/
CN

Cho
eleven
1L
Cho r
r
 b
Oq th


I o
about
rf
eight
r
(X
I &
 (
§1 s
00
t S
ABOUT; c
Q.
n
CO
a

Sya &amp;
Well
and
I
m
c oo
GL 1L
CO
t S
SI
f- S
vO
cs
rs with
-
-. §
a.
- ej l
eleven
I I m
"I
about
Tj-v
- S
S- S
n
I i
AT.
a
S 1
I
M
S
Well
ac
f
about
I
r
(S)
S f
F
I u
-

five
U
about
cc
Dyil
Ov
i §.
I e
n
Tt
MF
Hl r
N
h
ft
S
 f
in yo
O.
s
about
GL fM
I ё
I with
oo
 s
(S
f
n M
S (X
:
I
I

"
four
(E
MS
Ch oo
V
t

(N
OS
fN
r
 I
I
MSG
00
YU "
OO
n
, G4 t
- AT
“-A
with N 1 l
.I
a
I
ON G
about 5
2
.§
O n
r: n
Hl 5
MS 2
five:;
CU
N §.
x
f
 Y

f
(H
Y
"
s
g
u
66F59

S
;
r f
It
oo
00
G-1L G)
ffl
&
i
2o
ABOUT
cs
fS
s
i
I
Q.
§
00
-I
ou ts 4
2 g
G42
four
Yo
f ё
B
U
r
and OS I I I-I o .-. 0 e .0 pop
(N t
9
L
N
O
1L
Vd
IT)
H
t} (N YI
VO

§
X
,
s

ABOUT
 about
3
Oh oh n oh
 &
oh
S o i6
about.
N o
(S o
; i

P
H

1C
with
S
X u

f
as
 g

i

rt s. s CX6
(f

o | l


s
i
u X o V h
B. S.
GL 00
 one
S fN K &amp; I
 15
Isl
e I n
l m
" § five
ss
cho 5
2 "S
 S
m
 P

X
CJ

X o
l to
H
 tp
/
to and
5: tj
| Z
ri
I
I
TO
i
I
about.
I
o / 1
if
1L "L1
t
ch sh
in
Hf a ° s

(S
" five
§ five
about a
I s
n o
ff x
: $
S
u u u
one
g. to
2 b
 Th
five;
rh;
to
f
h: and
iff
Cho
00
r
Cho
s
fN 5
B
tN
to
 f
ri
f
Kl
u
u
-n
oo
V)
and
&
tt,
II

and
one§§
§five
i
g New compounds: A - l 1- (1-ethyl-2-tyrrolitsinil) methylamine acetyl} -5,11-dithydro-5-methyl bH-pyrido 2,3-Ь 11,4 bsnzodiazepin-6-one; B - 5,11-dihydro-11 - (- methoxypiperidino) acetyl-bH-pyrido 12,3-Ы (1,4 benzodiazepin6-one; B - 5,1 dihydro-3- (2-methylpiperidido) propionyl -6H-pyrido (2,3-1,4 benzodiazepin-6-one; G - 5,11-dihydro-11- (3-piperidinog1ropioshchl-bH-pyrido 2,3-1,4 benzodiazepin-6- he; D - 5,11-dihydro-11- (4-pyrrolidino-butyryl-bH-pyrido 2,3-b 1,4 benzodiazepin-6-one; examined for their retarding stress induced stress. Fed rats females with a body weight between 220 and 260 g are planted alone in small wire cages and then placed in a vertical position in a water bath having temperature at 23 ° C for 16 hours so that only tolov and sternum is on the surface of the water. The active substances are given orally to the rats 5-10 minutes before being immersed in water. 5 animals are taken for each substance. ml of 0.9% physiological
at 1500 mg / kg of 4 animals died 2.
at 1000 mg / kg of 5 animals died 2.
at 1000 mg / kg of 5 animals died 1.
at 2000 mg / kg of 5 animals died 3.
at 1500 mg / kg of 6 animals died 1,
The antispasmodic effect of substances A-D compared with atropine sulfate isteller Tables

权利要求:
Claims (5)
[1]
but weaker, and side effects of atropine are also weaker. solution of salt or 1 ml of 1% tylose solution. After 18 hours, the rats are sacrificed with an increased dose of chloroethyl, the stomach is taken out and opened along the greater curvature and stretched on a cork plate. The analysis is carried out according to the method of Marazzi-Uberti und Turba and according to the Takagi und Okabe method described above. The antispasmodic effect is determined in a test tube on the colon of a guinea pig. Acetylcholine is used to create the spastic condition, and atropinsulfate is used for comparison. The spasmodic is given 1 minute before giving an antispasmodic, the time of the action of the antispasmodic is 1 minute. In rats, it is also possible to observe that atropine-like side effects, such as, for example, inhibition of saliva secretion, are completely absent or substantially reduced when giving substances A-D. Acute toxicity is determined after oral administration of the active substances in unfed white mice weighing 18-20 g. Observation time is 14 days. The results of the experiments are summarized in table. 2. 27 Claims 1. Method for the preparation of benzodisepinone derivatives of general formula 1 where A is a straight or branched alkylene group with 1-5 carbon atoms; RI-free amino-tert.-butylamino M-cyclohexyl-N-methylamino-, dibenzylamino-benzylamino-, trimethoxybenzylamino-1-ethyl-2-pyrrolidanylmethylamino, 1-ethyl-3-piperi dinylamino-, 9-methyl-3,9 -diazabicyclo 3.3.1 nonan-3-nl-, 1, 2, 5, 6-tetrahydro-1-pyridyl-, 4-benzylpiperidino-, 1, 2, 3, 6, 7, 8, 9, 9-octahydro 4H-pyrazino (1,2-a) pyrimidin-1 (or-8) yl-, 3- or 4-hydroxypiperidine- or methoxypiperidino-, I, 2, 3, 4-tetrahydro-2ESOCHINOLIL-, 3-azaspiro (5 , 5) indan-3-yl, 4-oxopiperidinogroup or its ethylene ketal hexahydro-3-methyl-1-pyrimidinyl, thiomorpholine, 1-oxide-thiomorpholino, eksagidro-4-methyl-1H-1, 4-diazepin -il-, 2, 6-dimethylmorpholine | 1,4-diazabicyclo 4.3.0) non-4-IL-, 1, 2, 5, 6-tetrahydride) o-pyrid-yl-, (1-m thp-pyrrolidin-2-yl) ethylamino, (Bmethylpyrrolidin-2-yl) methylamino, {1-n-propylpyrrolidin-2-yl) methylamine-, (1-allyl-pyrro-lidin-2-yl) methylamino-, (1-n-butnp-pyrrolidine-2- yl) methylamino-, (1 -benzyl-pyrrolidin-2-yl) methylamino-, (furan-2-nl) methylamine ((tetrahydrof)) fan-2-yl) methylamine-, N- (1-methyl-pyrrolidin-2 -yl) methyl) -N-methyl-methyl amino, (1-methyl-pyrrolidin-3-yl) methyl (1-allyl-pyrrolidin-3-yl) methylamino group; R2 is a hydrogen atom, methyl,; moreover, RI may also mean dimethylamino-, diethylamino-, dipropylamide-di-isopropylamino-, di-n-butylamino-, di-isobutylamino-, pyrrolidino-, piperidine group, piperidine group, substituted with methyl or ethyl, or a morpholine group, if A is an unbranched or branched alkylene group with 2-5 carbon atoms, or their salts, characterized in that the compound is J i co-A-Nae where R and A are as defined above and Hat is a halogen atom; reacting with a compound of general formula III RI - X, where RI is as defined above; with the subsequent selection of the target product in free form or in the form of a salt.
[2]
2. A method according to claim 1, characterized in that the process is carried out in an inert solvent at a temperature from room temperature to the boiling point of the solvent.
[3]
3. The method according to PP.1 and 2, that is, that the process is carried out in the presence of a hydrogen halide binder.
[4]
4. Method according to paragraphs. 1-3, different. by using an excess of a compound of formula III as a hydrogen halide binder.
[5]
5. Method according to paragraphs. 1-3, characterized in that an alkali metal carbonate or bicarbonate or a tertiary organic amine is used as a hydrogen halide binder. Sources of information taken into account in the examination 1. USSR patent N 567407, cl. C 07 D 243/38, 1974.

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU797578A3|1981-01-15|Method of preparing benzodiazepinone derivatives or their salts

---

EP0469449B1|1997-10-01|Diazabicyclononyl derivatives as 5-HT3 receptor antagonists

---

US4783534A|1988-11-08|N-alkylnorscopines and acid addition salts thereof

---

ES2341560T3|2010-06-22|AMINAS N-ARILSULFONILHETEROCICLICAS REPLACED AS GAMMA-SECRETASE INHIBITORS.

---

US20040186127A1|2004-09-23|Novel deazapurines and uses thereof

---

GB2166726A|1986-05-14|Substituted benzoic acid alkylene bridged piperidyl amides

---

PL69767B1|1973-08-31|11-substituted 5 11-dihydro-6h-pyrido|benzodiazepin-6-ones [us3660380a]

---

SU772484A3|1980-10-15|Method of preparing benzodiazepinone derivatives or their salts

---

AU4208501A|2001-10-15|Novel derivatives and analogues of galanthamin

---

US20080262075A1|2008-10-23|Pyrrolidine Derivatives as Muscarinic Receptor Antagonists

---

EP0499995B1|1997-01-02|Piperidine derivatives

---

US4002632A|1977-01-11|Tetracyclic piperidino derivatives

---

US4362739A|1982-12-07|Pyrrolo|carbazole derivatives, compositions and use

---

GB2120662A|1983-12-07|New azepinoindoles, their production and pharmaceutical compositions containing them

---

GB1569251A|1980-06-11|Pyridobenzodiazepines

---

DE4227605C2|1995-02-16|17-Hydroxyiminomethyl-14beta-hydroxy-5β-androstane derivatives, processes for their preparation and pharmaceutical compositions containing them

---

EP0228825A1|1987-07-15|6,7,8,9-Tetrahydro-10-methylpyrido [1,2-a]indol-9-amines and derivatives thereof

---

EP0558923B1|2000-05-24|Diazabicyclo derivatives as 5-HT3 antagonists

---

US4228168A|1980-10-14|Azepino [1,2,3-lm]-β-carboline compounds and pharmaceutical composition thereof

---

DE2724478A1|1978-12-21|NEW, 11-POSITION SUBSTITUTED 5,11-DIHYDRO-6H-PYRIDO SQUARE CLAMP ON 2.3 SQUARE BRACKET TO SQUARE BRACKET ON 1.4 SQUARE BRACKET TO BENZODIAZEPIN-6-ONE, THE PROCESS FOR THEIR PRODUCTION AND THESE JOINTS DRUG

---

EP0977757B1|2003-10-15|9,10-diazatricyclo 4.2.1.1?2,5 ]decane and 9,10-diazatricyclo 3.3.1.1?2,6 ]decane derivatives having analgesic activity

---

D'Andrea et al.1991|trans-3, 4-Diaminopiperidines. Azacyclohexane congeners of. kappa. agonist U-50488

---

DD275243A5|1990-01-17|METHOD FOR PRODUCING NEW CONDENSED DIAZEPINONES

---

HUT70557A|1995-10-30|N,n&#39;-disubstituted amine derivative, pharmaceutical compositions containing them and process for producing the compounds and the compositions

---

US4428880A|1984-01-31|Azepino[4,5-d]indole derivatives and preparation thereof

同族专利:

---

公开号 | 公开日

---

BE867639A|1978-11-30|

---

GR64535B|1980-04-10|

---

NZ187428A|1981-01-23|

---

FI63233C|1983-05-10|

---

DK148233B|1985-05-13|

---

JPS6216952B2|1987-04-15|

---

ES470269A1|1979-01-01|

---

YU129478A|1983-02-28|

---

ATA367778A|1980-09-15|

---

NL7805848A|1978-12-04|

---

HU180540B|1983-03-28|

---

PL207192A1|1979-04-23|

---

DD135490A5|1979-05-09|

---

MY8100362A|1981-12-31|

---

US4210648A|1980-07-01|

---

DK239378A|1978-12-01|

---

FR2392991B1|1982-10-22|

---

AT361929B|1981-04-10|

---

FI63233B|1983-01-31|

---

HK19381A|1981-05-15|

---

SE7806287L|1978-12-01|

---

SE437831B|1985-03-18|

---

JPS543092A|1979-01-11|

---

FI781690A|1978-12-01|

---

AU3662478A|1979-12-06|

---

AU516712B2|1981-06-18|

---

GB1581500A|1980-12-17|

---

ZA783086B|1980-02-27|

---

IL54815A|1981-07-31|

---

IE46909B1|1983-11-02|

---

NO781880L|1978-12-01|

---

PL113999B1|1981-01-31|

---

BG28712A3|1980-06-16|

---

CH637956A5|1983-08-31|

---

FR2392991A1|1978-12-29|

---

IE781073L|1978-11-30|

---

PT68114A|1978-06-01|

---

CS202600B2|1981-01-30|

---

DK148233C|1985-10-21|

---

NO149065B|1983-10-31|

---

NO149065C|1984-02-08|

---

CA1081220A|1980-07-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

DE1795183B1|1968-08-20|1972-07-20|Thomae Gmbh Dr K|5,11-dihydro-6H-pyrido [2,3-b] [1,4] benzodiazepin-6-one derivatives and drugs|

---

US3691152A|1971-03-10|1972-09-12|Texaco Inc|Hydrodesulfurization and blending of residue-containing petroleum oil|GB2053187A|1979-07-09|1981-02-04|Grissmann Chem Ltd|Process for preparing pyrenzepine|

---

GR72993B|1980-01-24|1984-01-25|Crc Ricerca Chim|

---

IT1130973B|1980-03-17|1986-06-18|Microsules Argentina Sa De S C|PROCESS FOR THE PREPARATION OF DERIVATIVES OF 5,11-DI-HYDRO-6H-PYRID -BENZODIAZEPIN-6-ONE, FINAL AND INTERMEDIATE DERIVATIVES OF SYNTHESIS IN THIS WAY OBTAINED|

---

DE3212794A1|1982-04-06|1983-10-13|Basf Ag, 6700 Ludwigshafen|5,6-DIHYDRO-11-ALKYLENE-MORPHANTRIDIN-6-ONE, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM|

---

IT1212743B|1983-05-17|1989-11-30|Dompe Farmaceutici Spa|QUATERNARY SALTS OF BENZO DERIVATIVES [1,4] DIAZEPINONICS, PYRID [1,4] BENZODIAZEPINONICS, PRIDO [1,5] BENZODIAZEPINONICS AND THEIR PHARMACOLOGICAL LIFE ACTS|

---

IT1212742B|1983-05-17|1989-11-30|Dompe Farmaceutici Spa|DIBENZO DERIVATIVES [1,4] PYRID DIAZEPINONIC [1,4] BENZODIAZEPINONIC, PYRID [1,5] BENZODIAZEPINONIC AND THEIR PHARMACOLOGICAL ACTIVITY|

---

DE3626095A1|1986-07-31|1988-02-11|Thomae Gmbh Dr K|NEW SUBSTITUTED PYRIDO BENZODIAZEPIN-6-ONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

DE3643666A1|1986-12-20|1988-06-30|Thomae Gmbh Dr K|NEW CONDENSED DIAZEPINONE, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS|

---

DE3802334A1|1988-01-27|1989-08-10|Thomae Gmbh Dr K|NEW CONDENSED DIAZEPINONE, PROCESS FOR THEIR MANUFACTURE AND MEDICAMENTS CONTAINING THESE COMPOUNDS|

---

DE3820346A1|1988-06-15|1989-12-21|Thomae Gmbh Dr K|NEW CONDENSED DIAZEPINONE, PROCESS FOR THEIR MANUFACTURE AND MEDICAMENTS CONTAINING THESE COMPOUNDS|

---

DE3820347A1|1988-06-15|1989-12-21|Thomae Gmbh Dr K|USE OF 11-SUBSTITUTED 5,11-DIHYDRO-6H-PYRIDO BENZODIAZEPIN-6-ONEN FOR THE TREATMENT OF BRADYCARDIES AND BRADYARRHYTHMIES IN THE HUMAN AND VETERINARY MEDICINE|

---

US5264432A|1989-07-31|1993-11-23|Arzneimittelwerk Dresden G.M.B.H|5--5,10-dihydro-11H-dibenzo[b,e]diazepin-11-ones|

---

DE3930266A1|1989-09-11|1991-03-14|Thomae Gmbh Dr K|CONDENSED DIAZEPINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING THESE COMPOUNDS|

---

DE3930262A1|1989-09-11|1991-03-21|Thomae Gmbh Dr K|CONDENSED DIAZEPINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING THESE COMPOUNDS|

---

GB9000302D0|1990-01-06|1990-03-07|Pfizer Ltd|Muscarinic receptor antagonists|

---

US5418229A|1990-01-06|1995-05-23|Alker; David|Muscarinic receptor antagonists|

---

CA2573674A1|2004-07-16|2006-01-26|Proteosys Ag|Muscarinic antagonists with parp and sir modulating activity as agents for inflammatory diseases|

---

EP2387405A2|2009-01-13|2011-11-23|ProteoSys AG|Pirenzepine as an agent in cancer treatment|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

DE19772724478|DE2724478C2|1977-05-31|1977-05-31|5,11-Dihydro-6H-pyrido [2,3-b] [1,4] benzodiazepin-6-one derivatives, processes for their preparation and pharmaceuticals containing these compounds|

---